Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 9/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.40 |
| ▸ | USP2 | O75604 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14671074 | 0.90 | CYP2C9 (0.43) | CYP2C9CYP2D6CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL14671038 | 0.86 | CYP2C9 (0.47) | CYP2C9CYP2D6CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL22200882 | 0.83 | HPGD (0.39) | ALDH1A1USP2HPGD | |
| SCHEMBL25009341 | 0.81 | SMN1; SMN2 (0.41) | CYP2C9CYP2D6CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL15986907 | 0.81 | CYP2C9 (0.44) | CYP2C9CYP2D6CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL15984372 | 0.79 | OPRL1 (0.36) | CYP2C9CYP2D6CYP1A2ALDH1A1CYP2C19 | |
| SCHEMBL14670913 | 0.78 | MEN1 (0.38) | CYP2C9CYP2D6CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL2603248 | 0.77 | CYP1A2 (0.45) | CYP2C9CYP2D6CYP1A2ALDH1A1USP2 | |
| SCHEMBL17266096 | 0.77 | CYP2C9 (0.41) | CYP2C9CYP2D6CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL14670983 | 0.77 | CYP2C9 (0.58) | CYP2C9CYP2D6CYP1A2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226923-B2 | Spirocyclic molecules as protein kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-01-05 | — | — | US | disclosed |
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2014-08-28 | — | — | US | disclosed |
| WO-2013013308-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | MET, RET, ALK | CYP2C9 3313/4885CYP2D6 2246/4885CYP1A2 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.